Cargando…
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth d...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513326/ https://www.ncbi.nlm.nih.gov/pubmed/36240755 http://dx.doi.org/10.1016/j.xcrm.2022.100781 |
| _version_ | 1784798036098023424 |
|---|---|
| author | Fendler, Annika Shepherd, Scott T.C. Au, Lewis Wu, Mary Harvey, Ruth Wilkinson, Katalin A. Schmitt, Andreas M. Tippu, Zayd Shum, Benjamin Farag, Sheima Rogiers, Aljosja Carlyle, Eleanor Edmonds, Kim Del Rosario, Lyra Lingard, Karla Mangwende, Mary Holt, Lucy Ahmod, Hamid Korteweg, Justine Foley, Tara Barber, Taja Emslie-Henry, Andrea Caulfield-Lynch, Niamh Byrne, Fiona Deng, Daqi Kjaer, Svend Song, Ok-Ryul Queval, Christophe J. Kavanagh, Caitlin Wall, Emma C. Carr, Edward J. Caidan, Simon Gavrielides, Mike MacRae, James I. Kelly, Gavin Peat, Kema Kelly, Denise Murra, Aida Kelly, Kayleigh O’Flaherty, Molly Shea, Robyn L. Gardner, Gail Murray, Darren Popat, Sanjay Yousaf, Nadia Jhanji, Shaman Tatham, Kate Cunningham, David Van As, Nicholas Young, Kate Furness, Andrew J.S. Pickering, Lisa Beale, Rupert Swanton, Charles Gandhi, Sonia Gamblin, Steve Bauer, David L.V. Kassiotis, George Howell, Michael Nicholson, Emma Walker, Susanna Wilkinson, Robert J. Larkin, James Turajlic, Samra |
| author_facet | Fendler, Annika Shepherd, Scott T.C. Au, Lewis Wu, Mary Harvey, Ruth Wilkinson, Katalin A. Schmitt, Andreas M. Tippu, Zayd Shum, Benjamin Farag, Sheima Rogiers, Aljosja Carlyle, Eleanor Edmonds, Kim Del Rosario, Lyra Lingard, Karla Mangwende, Mary Holt, Lucy Ahmod, Hamid Korteweg, Justine Foley, Tara Barber, Taja Emslie-Henry, Andrea Caulfield-Lynch, Niamh Byrne, Fiona Deng, Daqi Kjaer, Svend Song, Ok-Ryul Queval, Christophe J. Kavanagh, Caitlin Wall, Emma C. Carr, Edward J. Caidan, Simon Gavrielides, Mike MacRae, James I. Kelly, Gavin Peat, Kema Kelly, Denise Murra, Aida Kelly, Kayleigh O’Flaherty, Molly Shea, Robyn L. Gardner, Gail Murray, Darren Popat, Sanjay Yousaf, Nadia Jhanji, Shaman Tatham, Kate Cunningham, David Van As, Nicholas Young, Kate Furness, Andrew J.S. Pickering, Lisa Beale, Rupert Swanton, Charles Gandhi, Sonia Gamblin, Steve Bauer, David L.V. Kassiotis, George Howell, Michael Nicholson, Emma Walker, Susanna Wilkinson, Robert J. Larkin, James Turajlic, Samra |
| author_sort | Fendler, Annika |
| collection | PubMed |
| description | Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination. |
| format | Online Article Text |
| id | pubmed-9513326 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95133262022-09-27 Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer Fendler, Annika Shepherd, Scott T.C. Au, Lewis Wu, Mary Harvey, Ruth Wilkinson, Katalin A. Schmitt, Andreas M. Tippu, Zayd Shum, Benjamin Farag, Sheima Rogiers, Aljosja Carlyle, Eleanor Edmonds, Kim Del Rosario, Lyra Lingard, Karla Mangwende, Mary Holt, Lucy Ahmod, Hamid Korteweg, Justine Foley, Tara Barber, Taja Emslie-Henry, Andrea Caulfield-Lynch, Niamh Byrne, Fiona Deng, Daqi Kjaer, Svend Song, Ok-Ryul Queval, Christophe J. Kavanagh, Caitlin Wall, Emma C. Carr, Edward J. Caidan, Simon Gavrielides, Mike MacRae, James I. Kelly, Gavin Peat, Kema Kelly, Denise Murra, Aida Kelly, Kayleigh O’Flaherty, Molly Shea, Robyn L. Gardner, Gail Murray, Darren Popat, Sanjay Yousaf, Nadia Jhanji, Shaman Tatham, Kate Cunningham, David Van As, Nicholas Young, Kate Furness, Andrew J.S. Pickering, Lisa Beale, Rupert Swanton, Charles Gandhi, Sonia Gamblin, Steve Bauer, David L.V. Kassiotis, George Howell, Michael Nicholson, Emma Walker, Susanna Wilkinson, Robert J. Larkin, James Turajlic, Samra Cell Rep Med Report Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination. Elsevier 2022-09-27 /pmc/articles/PMC9513326/ /pubmed/36240755 http://dx.doi.org/10.1016/j.xcrm.2022.100781 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Report Fendler, Annika Shepherd, Scott T.C. Au, Lewis Wu, Mary Harvey, Ruth Wilkinson, Katalin A. Schmitt, Andreas M. Tippu, Zayd Shum, Benjamin Farag, Sheima Rogiers, Aljosja Carlyle, Eleanor Edmonds, Kim Del Rosario, Lyra Lingard, Karla Mangwende, Mary Holt, Lucy Ahmod, Hamid Korteweg, Justine Foley, Tara Barber, Taja Emslie-Henry, Andrea Caulfield-Lynch, Niamh Byrne, Fiona Deng, Daqi Kjaer, Svend Song, Ok-Ryul Queval, Christophe J. Kavanagh, Caitlin Wall, Emma C. Carr, Edward J. Caidan, Simon Gavrielides, Mike MacRae, James I. Kelly, Gavin Peat, Kema Kelly, Denise Murra, Aida Kelly, Kayleigh O’Flaherty, Molly Shea, Robyn L. Gardner, Gail Murray, Darren Popat, Sanjay Yousaf, Nadia Jhanji, Shaman Tatham, Kate Cunningham, David Van As, Nicholas Young, Kate Furness, Andrew J.S. Pickering, Lisa Beale, Rupert Swanton, Charles Gandhi, Sonia Gamblin, Steve Bauer, David L.V. Kassiotis, George Howell, Michael Nicholson, Emma Walker, Susanna Wilkinson, Robert J. Larkin, James Turajlic, Samra Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer |
| title | Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer |
| title_full | Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer |
| title_fullStr | Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer |
| title_full_unstemmed | Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer |
| title_short | Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer |
| title_sort | functional immune responses against sars-cov-2 variants of concern after fourth covid-19 vaccine dose or infection in patients with blood cancer |
| topic | Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513326/ https://www.ncbi.nlm.nih.gov/pubmed/36240755 http://dx.doi.org/10.1016/j.xcrm.2022.100781 |
| work_keys_str_mv | AT fendlerannika functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT shepherdscotttc functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT aulewis functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT wumary functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT harveyruth functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT wilkinsonkatalina functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT schmittandreasm functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT tippuzayd functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT shumbenjamin functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT faragsheima functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT rogiersaljosja functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT carlyleeleanor functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT edmondskim functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT delrosariolyra functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT lingardkarla functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT mangwendemary functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT holtlucy functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT ahmodhamid functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT kortewegjustine functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT foleytara functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT barbertaja functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT emsliehenryandrea functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT caulfieldlynchniamh functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT byrnefiona functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT dengdaqi functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT kjaersvend functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT songokryul functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT quevalchristophej functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT kavanaghcaitlin functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT wallemmac functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT carredwardj functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT caidansimon functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT gavrielidesmike functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT macraejamesi functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT kellygavin functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT peatkema functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT kellydenise functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT murraaida functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT kellykayleigh functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT oflahertymolly functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT shearobynl functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT gardnergail functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT murraydarren functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT popatsanjay functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT yousafnadia functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT jhanjishaman functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT tathamkate functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT cunninghamdavid functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT vanasnicholas functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT youngkate functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT furnessandrewjs functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT pickeringlisa functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT bealerupert functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT swantoncharles functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT gandhisonia functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT gamblinsteve functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT bauerdavidlv functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT kassiotisgeorge functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT howellmichael functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT nicholsonemma functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT walkersusanna functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT wilkinsonrobertj functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT larkinjames functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer AT turajlicsamra functionalimmuneresponsesagainstsarscov2variantsofconcernafterfourthcovid19vaccinedoseorinfectioninpatientswithbloodcancer |